While there may not be new DSCSA regulations going live in 2021, that doesn’t mean manufacturers can take a break from thinking about their DSCSA and serialization strategy this year. The 2023 requirements still loom ahead.
Envision Pharma Group acquires Two Labs to advance its position as a global strategic partner to pharma and create a unique and unrivaled launch excellence offering
Competitive intelligence is an extremely valuable step of any new drug or indication launch. From providing insight into a crowded market to guiding allocation of budget, this research is beneficial no matter what stage of the launch process you’re in.
The COVID-19 pandemic is unprecedented and unpredictable. Nevertheless, we are remaining flexible as we continue to support pharmaceutical manufacturers and their life-changing work.
3PLs aren’t just a logistics solution – they’re an extension of your business, and few things are as important to the success of your launch as selecting the right 3PL partner.
The launch of a new drug is a complex process. With so many factors playing into the final outcome, it may seem impossible to predict whether or not any given launch will be a success.
Globalizing Medical Affairs can often pull teams away from focusing on their local needs. Our Medical Affairs solution identifies challenges that impede globalization efforts and recommends tactics for optimizing both local and global operations.
The pharma industry can be complicated, but the more intel you have – market or competitive, the better you’ll be able to make decisions that lead you to success.
